focus -WSS

focus

author：entertainment 2025-09-04 22:02:43 - browse：9

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： David Sabatini, ex

entertainment

explore

WSS

Focused ultrasound for uterine fibroids: an uphill battle

Dark money group runs ads on China biotech bill

Addiction doctors spar with methadone clinics over legislation

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Food as medicine: Medically tailored meals may get standardized

Prosthetic arm enables patients to feel the objects they grip

entertainment

focus

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Drug repurposing or repositioning? The language matters

Heat waves linked to early deliveries, preterm births in new study

Novavax promises a turnaround & Lilly roils the obesity market

Heat waves linked to early deliveries, preterm births in new study

Dobbs anniversary: the lost opportunity of abortion as health care

Decaf coffee targeted by food safety group under obscure FDA rule

Wikipedia

Washington mulls new rules to avert another Change Healthcare

David Sabatini, ex

Report: NIH

David Sabatini, ex

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Why the world’s most expensive drug might be worth the price

entertainment

explore

explore

entertainment